Indaptus Therapeutics (INDP) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Surrozen (SRZN) has outperformed Indaptus Therapeutics (INDP) over the past year, gaining 82.9% versus a loss of 38.8%. Over five years, SRZN leads with a -73.5% price change compared with -99.0% for INDP. Indaptus Therapeutics is the larger company by market cap ($301.1 million vs $295.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDP | SRZN |
|---|---|---|
| Share price | $2.26 | $25.15 |
| Market cap | $301.13M | $295.54M |
| 1-day change | -12.74% | -4.65% |
| YTD return | -22.34% | +11.26% |
| 1-year return | -38.75% | +82.87% |
| 5-year return | -98.97% | -73.48% |
| EPS (TTM) | $-6.15 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.96 | $37.83 |
| 52-week low | $0.92 | $11.39 |
| Distance from 52-week high | -62.08% | -33.53% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +92.48% |
| Average volume | 832.95K | 471.01K |
| Shares outstanding | 133.24M | 11.75M |
| Employees | 5 | 44 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed INDP by 121.6 percentage points over the past year.
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Healthcare · Biotechnology · 5 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Healthcare · Biotechnology · 44 employees
INDP vs SRZN FAQ
Which is bigger, Indaptus Therapeutics or Surrozen?
Indaptus Therapeutics (INDP) is larger, with a market capitalization of $301.13M compared with $295.54M for Surrozen (SRZN).
Which stock has performed better over the past year, INDP or SRZN?
SRZN returned +82.87% over the past 12 months, compared with -38.75% for INDP (price return, excluding dividends). Past performance does not predict future results.
Are Indaptus Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.